Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors

Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate autoreactivity, immune checkpoint inhibitor th...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinmann, Sophia C, Pisetsky, David S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900913/
https://www.ncbi.nlm.nih.gov/pubmed/31816080
http://dx.doi.org/10.1093/rheumatology/kez308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900913/
https://www.ncbi.nlm.nih.gov/pubmed/31816080
http://dx.doi.org/10.1093/rheumatology/kez308

Ejemplares similares